Giuseppe Cullaro1, Elizabeth C Verna2, Charles E McCulloch3, Jennifer C Lai1. 1. Department of Medicine, University of California-San Francisco, San Francisco, California, USA. 2. Center for Liver Disease and Transplantation, Columbia University, Vagelos College of Physicians and Surgeons, New York, New York, USA. 3. Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Abstract
BACKGROUND AND AIMS: We investigated the impact of the inclusion of kidney dysfunction type on the discrimination and calibration of the Model for End-Stage Liver Disease with sodium (MELD-Na-KT) score. APPROACH AND RESULTS: We included all adults listed for ≥90 days without exception points from January 1, 2008, through December 31, 2018. We defined kidney dysfunction types as follows: acute kidney disease (AKD; an increase of ≥0.3 mg/dL or ≥50% in serum creatinine in the last 7 days or fewer than 72 days of hemodialysis), chronic kidney disease (CKD; an estimated glomerular filtration rate <60 ml/min/1.73 m2 for 90 days or ≥72 days of hemodialysis), AKD on CKD (met both definitions), or none (met neither definition). We then developed and validated a multivariable survival model with follow-up beginning at the first assessment after 90 days from waitlist registration and ending at the time of death, waitlist removal, or 90 days from enrollment in this study. The predictor variables were MELD-Na and the derived MELD-Na-KT model. In the derivation cohort, kidney dysfunction type was significantly associated with waitlist mortality after controlling for MELD-Na. There was a significant linear interaction between kidney dysfunction type and MELD-Na score. In the validation cohort, we saw an improvement in the discrimination of the model with an increase in the c-index from 0.76 with MELD-Na to 0.78 with MELD-Na-KT (p = 0.002) and a net reclassification index of 10.8% (95% CI, 1.9%-11.4%). The newly derived MELD-Na-KT model had lower Brier scores (MELD-Na-KT 0.042 vs. MELD-Na 0.053). CONCLUSIONS: This study demonstrates the feasibility and the potential for objectively defined kidney dysfunction types to enhance the prognostication of waitlist mortality provided by the MELD-Na score.
BACKGROUND AND AIMS: We investigated the impact of the inclusion of kidney dysfunction type on the discrimination and calibration of the Model for End-Stage Liver Disease with sodium (MELD-Na-KT) score. APPROACH AND RESULTS: We included all adults listed for ≥90 days without exception points from January 1, 2008, through December 31, 2018. We defined kidney dysfunction types as follows: acute kidney disease (AKD; an increase of ≥0.3 mg/dL or ≥50% in serum creatinine in the last 7 days or fewer than 72 days of hemodialysis), chronic kidney disease (CKD; an estimated glomerular filtration rate <60 ml/min/1.73 m2 for 90 days or ≥72 days of hemodialysis), AKD on CKD (met both definitions), or none (met neither definition). We then developed and validated a multivariable survival model with follow-up beginning at the first assessment after 90 days from waitlist registration and ending at the time of death, waitlist removal, or 90 days from enrollment in this study. The predictor variables were MELD-Na and the derived MELD-Na-KT model. In the derivation cohort, kidney dysfunction type was significantly associated with waitlist mortality after controlling for MELD-Na. There was a significant linear interaction between kidney dysfunction type and MELD-Na score. In the validation cohort, we saw an improvement in the discrimination of the model with an increase in the c-index from 0.76 with MELD-Na to 0.78 with MELD-Na-KT (p = 0.002) and a net reclassification index of 10.8% (95% CI, 1.9%-11.4%). The newly derived MELD-Na-KT model had lower Brier scores (MELD-Na-KT 0.042 vs. MELD-Na 0.053). CONCLUSIONS: This study demonstrates the feasibility and the potential for objectively defined kidney dysfunction types to enhance the prognostication of waitlist mortality provided by the MELD-Na score.
Authors: Maria Kalafateli; Fred Wickham; Maria Burniston; Evangelos Cholongitas; Eleni Theocharidou; Matteo Garcovich; James O'Beirne; Rachel Westbrook; Gioacchino Leandro; Andrew K Burroughs; Emmanuel A Tsochatzis Journal: Hepatology Date: 2016-11-29 Impact factor: 17.425
Authors: Ashwani K Singal; Song Ong; Sanjaya K Satapathy; Patrick S Kamath; Russel H Wiesner Journal: Transpl Int Date: 2019-02-21 Impact factor: 3.782
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Lakhmir S Chawla; Rinaldo Bellomo; Azra Bihorac; Stuart L Goldstein; Edward D Siew; Sean M Bagshaw; David Bittleman; Dinna Cruz; Zoltan Endre; Robert L Fitzgerald; Lui Forni; Sandra L Kane-Gill; Eric Hoste; Jay Koyner; Kathleen D Liu; Etienne Macedo; Ravindra Mehta; Patrick Murray; Mitra Nadim; Marlies Ostermann; Paul M Palevsky; Neesh Pannu; Mitchell Rosner; Ron Wald; Alexander Zarbock; Claudio Ronco; John A Kellum Journal: Nat Rev Nephrol Date: 2017-02-27 Impact factor: 28.314
Authors: Sumeet K Asrani; Linda W Jennings; W R Kim; Patrick S Kamath; Josh Levitsky; Mitra K Nadim; Giuliano Testa; Michael D Leise; James F Trotter; Goran Klintmalm Journal: Hepatology Date: 2020-01-29 Impact factor: 17.425